Skip to main content

5th March 2020

Trials of a new drug have shown it can ease symptoms of a chronic cough

Trials of the drug Gefapixant, show that at doses under 50mg, 80% of patients with chronic coughing had a significant clinical response of reduced coughing
Trials of a new drug have shown it can ease symptoms of a chronic cough
Photo: Petr Kratochvi @ Public Domain Pictures

Two trials of a new drug, referred to as Gefapixant, has shown at low doses to ease distressing symptoms of a chronic cough with very little side effects.

Chronic coughing is thought to affect between 4-10% of the population, which can be caused by several factors such as asthma, gastroesophageal reflux disease, pneumonia, bronchitis and postnasal drip.

Researcher Jacky Smith, a Professor of Respiratory Medicine at the University of Manchester and consultant at Wythenshawe Hospital, said: “This drug has exciting prospects for patients who suffer from the often distressing condition of chronic cough”.

Although the drug can reduce the sense of taste at high doses, up to 50mg the effect of the drug does not impair senses. The study, published in Lancet Respiratory Medicine Today, shows that in a 12-week trial of 253 patients, 80% of patients had a clinically significant response to a dose of 50mg.

Results showed that a dose of 7.5mg reduced the coughing by 52%, 20mg by 52% and 50mg by 67% from baseline. However, around a quarter did not respond to the drug.

Both studies were randomised and double blinded, which means that none of the participants knew who received the treatment. The drug is now in two larger, global phase 3 trials, carried out to confirm and expand on the safety and effectiveness results from previous research.

This new trial is significant because no effective treatments for coughs have met clinical needs, and no new therapies have been approved in the last 50 years, says Professor Smith.

Interestingly, the drug was initially developed as a pain killer, until the researchers discovered it impacted chronic cough quite significantly. Gefapixant targets P2X3receptors in the nerves which control coughing, which was what the team monitored to see the drug’s impact.

Professor Smith added: “We can’t yet say when or if this drug will be available on prescription, however, if the phase 3 trial is successful then it would certainly be a major step towards everyday use”.

Chronic cough can greatly impact someone’s everyday life. Retired journalist Nick Peake from Warrington, has been suffering for 25 years from the debilitating condition. He said: “Coughing has blighted my life: every day without fail I cough for the first two hours…it wears me out…I’m thoroughly fed up with it and desperate for a cure to be found”.

More Coverage

How reindeers keep their cool

With all the exercise reindeers supposedly get up to (think flying across the globe) how do they keep cool with such a well-insulating coat? Here’s the answer

Eternal youth explored- new breakthroughs in revolutionising ageing

As botox becomes more of a staple than a pop-star luxury, longevity research is becoming a much invested research area. Here’s how the UK is joining the science of ‘eternal youth’

From fusion to seclusion: the increasing isolation of scientists in Iran and Russia

Increasing international tensions and sanctions have left researchers isolated from the global scientific community

Science in the news 3: Brain implants, rediscovered mammals and mentally time-travelling rats

From long-lost animals to rodent imagination, here’s a collection of the most exciting stories of science in the news